Jes Pa Pregnancy Mra Consideration

---
name: jes-pa-pregnancy-mra-consideration
description: Suggests considering mineralocorticoid receptor antagonists when benefits outweigh risks in pregnant or preconception PA patients with uncontrolled hypertension and hypokalemia. Triggered when standard therapy fails and clinicians ask 'Should I consider MRAs despite pregnancy?' or when assessing risk‑benefit of MRA use.
---

# Evaluate MRA use in PA patients during pregnancy or preconception

## STEP 1 — Gather Information
Collect pregnancy status (gestational age), blood pressure, serum potassium, current antihypertensives (especially pregnancy‑safe agents), hypertension control, hypokalemia severity, and prior response to conventional therapy.  
**Action:** Proceed to assess whether hypertension remains uncontrolled and hypokalemia persists despite maximal tolerated pregnancy‑safe therapy.

## STEP 2 — Rule In / Rule Out
If office BP ≥140/90 mm Hg **and** serum K+ <3.5 mmol/L despite using the highest tolerated dose of pregnancy‑safe antihypertensives (labetalol, nifedipine after 20 weeks, methyldopa) → **Rule in** for MRA consideration.  
Otherwise → **Rule out** (do not initiate an MRA).  
**Decision:** Move to stratification only when ruled in.

## STEP 3 — Classify or Stratify
Stratify by gestational age:  
- **First trimester (<14 weeks):** avoid spironolactone (anti‑androgen risk); consider eplerenone or esaxerenone if MRA deemed essential.  
- **Second/third trimester (≥14 weeks):** spironolactone may be used with close monitoring.  
**Action:** Select the appropriate MRA agent based on trimester and safety profile.

## STEP 4 — Decide
Initiate low‑dose MRA (spironolactone 25 mg daily **or** eplerenone 1.25 mg daily), re‑check serum potassium and blood pressure after 5–7 days, titrate upward if needed while avoiding hyperkalemia, and do **not** combine eplerenone or esaxerenone with potassium supplements.  
**Action:** Prescribe, monitor, and adjust as indicated.

## Clinical Guardrails / Mimics / Pitfalls
Avoid spironolactone in the first trimester due to anti‑androgen effects; monitor for hyperkalemia especially with concomitant ACE‑I/ARB or CKD; do not use potassium supplements with eplerenone/esaxerenone; prioritize α‑methyldopa, hydralazine, labetalol, or nifedipine (after 20 weeks) before considering MRAs; counsel patients on potential fetal risks and obtain informed consent.

## Concrete Clinical Example
A 32‑year‑old woman at 18 weeks gestation with biopsy‑proven PA presents with BP 152/96 mm Hg on labetalol 200 mg BID and serum K+ 2.9 mmol/L. Hypertension is uncontrolled and hypokalemia persists despite maximal labetalol. After discussing risks, spironolactone 25 mg daily is started; K+ rises to 3.8 mmol/L and BP improves to 138/86 mm Hg at one‑week follow‑up, dose is maintained with weekly K+ checks.

**Source:** Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2021